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Clinical Consequences of Antibody Formation, Serum
Concentrations, and HLA-Cw6 Status in Psoriasis Patients
on Ustekinumab
Eline De Keyser, MD,* Celine I. Busard, MD,† Sven Lanssens, MD,* Lieve Meuleman, MD,‡
Barbara A. Hutten, MD, PhD,§ Antonio Costanzo, MD, PhD,¶ Juul M. van den Reek, MD, PhD,║
Jeffrey Zweegers, MD, PhD,║ Jo Lambert, MD, PhD,* and Phyllis I. Spuls, MD, PhD†
Background: Ustekinumab for the treatment of psoriasis is
currently administered in a standard dosing regimen. However,
some patients tend to benefit from alternative dosing regimens, a step
toward personalized medicine.
Methods: To investigate the role of ustekinumab serum concen-
trations, anti-ustekinumab antibodies [AUA] and HLA-Cw6 status as
tools for optimizing ustekinumab treatment, a multicenter pro-
spective cohort study was conducted at an academic hospital with
affiliated nonacademic hospitals in Belgium (cohort 1) and 2
academic hospitals in the Netherlands (cohort 2 and 3). Patients
with plaque-type psoriasis were eligible if treated with ustekinumab
for $16 weeks. Serum samples and Psoriasis Area and Severity
Index scores were obtained at baseline, week 16, 28, 40, 52, and/
or $64 of ustekinumab treatment.
Results: A total of 137 patients with 229 observations for serum
concentrations and AUA and 61 observations for HLA-Cw6 status
were included. Presence of AUA (prevalence of 8.7%) was
significantly associated with a diminished clinical response (P =
0.032). The median ustekinumab trough concentration was 0.3
mcg/mL (,0.02–3.80). No differences in serum concentrations were
observed between moderate to good responders and nonresponders
(P = 0.948). Serum trough concentrations were not affected by
methotrexate comedication. Prevalence of HLA-Cw6 positivity
was 41% with no statistically significant difference in clinical
response between HLA-Cw6–positive and HLA-Cw6–negative pa-
tients (P = 0.164).
Conclusions: The presence of AUA was associated with treatment
failure in this patient population; measurement of AUA may
therefore be a candidate marker for personalized pharmacotherapy.
The clinical utility of ustekinumab serum trough concentrations or
HLA-Cw6 status determination remains less clear. Further explora-
tion on the potential of measuring ustekinumab serum concentrations
and other biomarkers in predicting therapy outcomes should be
encouraged.
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INTRODUCTION
Improved knowledge of the underlying molecular
mechanisms involved in the pathogenesis of immune-
mediated inflammatory diseases resulted in novel-targeted
biologic therapies, which greatly advanced psoriasis care over
the last decade. Currently registered biologics for psoriasis
include the tumor necrosis factor inhibitors adalimumab,
infliximab and etanercept, the interleukin (IL)-17 inhibitors
secukinumab, ixekizumab, and brodalumab, the IL-12/IL-23
inhibitor ustekinumab, and p19/IL-23 inhibitor guselkumab.
Although they all inhibit proinflammatory cytokines, they
differ in composition, efficacy, and their pharmacokinetic and
pharmacodynamic behavior. For more than a decade now,
physicians have used standard recommended dosing regimens
to treat psoriasis patients resulting in remarkable improve-
ments in psoriasis treatment outcomes.1–3 However, some
patients fail to achieve desired outcomes or fail to maintain
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improvement over time.4 Various theories have been investi-
gated elaborately to address this problem, including immuno-
genicity.5–7 Available evidence demonstrates that
antiadalimumab and anti-infliximab antibodies are associated
with a decreased treatment response. However, the signifi-
cance of antiustekinumab antibodies (AUA) is less clear.8,9
Other factors that might contribute to loss of response
include patient or disease factors (such as extent and severity
or body weight) that lead to variable serum concentrations
among patients over time.10 Recently, we have proposed
a therapeutic range for adalimumab, based on a significant
association between clinical response [Psoriasis Area and
Severity Index (PASI)] and serum trough concentrations.11
The defined therapeutic range suggested that a third of the
patients were actually overtreated, which may lead to unnec-
essary higher costs and increased risk of adverse events.12,13
Ustekinumab is generally administered in a standard
weight-dependent treatment regimen at week 0, 4, and every
12 weeks thereafter. Currently, limited evidence on therapeu-
tic drug monitoring is available. With this study, we aim to
determine whether ustekinumab serum trough concentrations,
AUA and HLA-Cw6 status are associated with clinical
response to identify potential tools for ustekinumab drug
monitoring.
MATERIALS AND METHODS
Participants
Patients were eligible if they were $18 years of age,
suffering from plaque-type psoriasis, and treated with subcu-
taneous ustekinumab for a minimum of 16 weeks. Ustekinu-
mab dosing and interval were generally administered in
a standard weight-dependent treatment regimen (dose of 45
mg for patients ,100 kg and 90 mg for patients $100 kg)
every 12 weeks. However, dosing and interval could be
adjusted in case of treatment failure (based on clinical
response, not on pharmacokinetic outcomes) according to
daily clinical practice. Patients were recruited from different
centers: The Ghent University Hospital and nonacademic
affiliated hospitals in Belgium (cohort 1) and the Academic
Medical Center and Radboud University Medical Center in
the Netherlands (cohort 2 and 3). Patient recruitment started
in January 2011 and ended in August 2015. Patient demo-
graphics [age, sex, body mass index, disease duration, diag-
nosis of psoriatic arthritis, previous biologic treatment,
disease severity at initiation of ustekinumab therapy (PASI
baseline)] and treatment characteristics [ustekinumab dosing
and concomitant use of methotrexate (MTX)] were collected
at study entry.
Serum Trough Concentrations, AUA, HLA-
Cw6 Status, and Determination of Clinical
Response
At baseline, week 16, week 28, week 40, week 52, and/
or $week 64, serum samples were collected to determine
ustekinumab trough concentrations, AUA and HLA-Cw6 sta-
tus, and PASI assessment was performed to determine clinical
response.
The serum samples, obtained within 3 days before
ustekinumab administration, were each centrifuged for 10
minutes at 1500g. Serum samples from cohort 1 and 3 were
stored at 280 degrees, whereas samples of cohort 2 were kept
at 220 degrees, until they were sent batchwise to the Labora-
tory for Monoclonal Therapeutics, Sanquin Diagnostic
Services, Amsterdam, the Netherlands. Ustekinumab trough
concentrations were determined using an enzyme-linked immu-
nosorbent assay (ELISA). This assay is based on the principle
that ustekinumab is captured through its ability to bind IL-12
and rabbit antiustekinumab for the detection of ustekinu-
mab.14,15 Results were reported in micrograms per milliliter
(mcg/mL). Detection of AUA was performed through a radio-
immunoassay, which measures specific high-avidity IgG anti-
bodies against ustekinumab by an antigen-binding test. These
results were converted into arbitrary units (AUs) per milliliter,
with a cutoff value for positivity set at 12 AU/mL.16,17
Serum samples to determine ustekinumab trough con-
centrations and the presence of AUA were collected from all
study patients. In cohort 1, HLA-Cw6 status was determined
additionally. Samples for HLA-Cw6 allele genotyping were
stored at 2808C, and DNA was extracted from leukocytes
with the Promega Kit (ReliaPrep Large Volume HT gDNA
Isolation System; Promega, Madison, WI). Polymerase chain
reaction was performed with allele-specific primers: 50-TAC-
TACAACCAGAGCGAGGA-30 and 50-GGTCGAGCCATA-
CATCCA-30. Results were interpreted as either positive or
negative. All methods were performed according to the man-
ufacturer’s instructions.
To assess clinical response, PASI and mean change in
PASI (DPASI) were obtained, and patients were classified as
nonresponder (DPASI ,50.00%), moderate responder
(DPASI 50.00%–74.99%), or good responder (DPASI
75.00%–100.00%).
Statistical Analysis
SPSS Statistics 22.0 (IBM, Armonk, NY) was used for
the statistical analysis of all data. To compare baseline
characteristics between the 3 cohorts and between subgroups
of patients, a Fisher exact test was used for categorical
variables and Mann–Whitney U or Kruskal–Wallis tests were
used for continuous variables. The associations between
serum trough concentrations, AUA, and clinical response
were evaluated using a linear mixed model. To ensure results
would not be influenced by transitioning from another bio-
logic or concomitant use of MTX, these factors were ac-
counted for. A Fisher exact test was used to compare clinical
response between HLA-Cw6–positive and HLA-Cw6–
negative patients. For each test, a P value ,0.05 was con-
sidered statistically significant.
Ethics
Approval for this multicenter cohort study was obtained
from the medical ethics committees of all participating
hospitals, and all patients gave their written informed consent
before participation. The study is being conducted according
to the principles of the Declaration of Helsinki and in
accordance with the Medical Research Involving Human
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Subjects Act (WMO) and other relevant guidelines, regula-
tions, and acts.
RESULTS
Study Population
Of 141 eligible patients, 2 patients refused participation,
and 2 patients were excluded as these patients had isolated
nail psoriasis. Consequently, 137 patients were included in
the cohort (respectively, 62, 48, and 27 patients in cohort 1, 2,
and 3). Table 1 demonstrates demographic characteristics,
which were comparable between cohorts. Patients (69.1%
male) had a high body mass index [28.9 (6 6.1) kg/m2],
a mean disease duration of 23.6 6 12.9 years, and a mean
PASI of 14.2 6 7.6 at initiation of ustekinumab treatment.
Thirty patients (21.9%) were diagnosed with psoriatic arthri-
tis, and most patients (76.8%) received other biologic treat-
ment(s) before ustekinumab. Twenty-five of 137 patients
(18.2%) did not receive the standard ustekinumab dosing
and schedule. In these patients dosing was adjusted based
on clinical response. Seven patients with a body weight of
93–99 kg received 90 mg, and 6 patients with a body weight
of 101–105 kg received 45 mg. Twelve patients received
ustekinumab every 10 weeks instead of every 12 (due to
insufficient response).
In total, 43 patients (31.2%) were treated with usteki-
numab 90 mg and 15 patients (10.9%) used MTX
comedication.
Data on serum trough concentrations, AUA, and
clinical response were collected in all study patients. Data
were collected at a single time point in 77 patients and at
repeated time points in 60 patients (in 28 patients at 2 time
points and in 32 patients at 3 time points). Data were collected
in 75 patients at week 16, in 64 patients at week 28, in 10
patients at week 40, in 42 patients at week 52, and in 38
patients after $64 weeks. Subsequently, during this study,
229 observations for serum trough concentrations, AUA,
and clinical response were obtained. At week 16, week 28,
week 40–52, and $64, 34.7, 32.8, 48.1, and 65.8% of pa-
tients achieved PASI 75, respectively.
Ustekinumab Serum Trough Concentrations
The median (range) serum trough concentration was 0.3
mcg/mL (,0.02–3.80). Four patients had undetectable serum
trough concentrations (,0.02) at week 16. At week 28, 40,
52, and $64 no undetectable serum trough concentrations
were observed. No statistically significant difference in trough
concentrations was observed for patients receiving 45 mg
versus 90 mg, with median (range) values of 0.30 mcg/mL
(,0.02–3.60) and 0.40 (,0.02–3.80) mcg/mL, respectively
(P = 0.14). Patients who used MTX comedication (n = 15,
10.9% of study population; 26 observations) demonstrated
ustekinumab trough concentrations similar to patients on us-
tekinumab monotherapy: 0.30 mcg/mL (,0.02–3.60) and
0.30 mcg/mL (,0.02–3.80), respectively (P = 0.95).
No statistically significant difference was found in
serum trough concentrations between moderate to good
responders and nonresponders [median (range); 0.3 (,0.02–
3.80), 0.3 (,0.02–3.60), and (,0.02–1.96), respectively, P =
0.948; Fig 1]. In addition, no significant correlation was
found between ustekinumab trough levels and ΔPASI (P =
0.302).
Development of AUA
AUA were detected in 12 of 137 patients (8.7%). In 3
of these patients, AUA were cleared during the study. Two of
these patients remained nonresponders, and 1 patient
achieved a good clinical response when AUA were cleared.
In the other patients AUA persisted during the study (n = 5) or
the evolution of AUA status remained unknown (n = 4), out
of which AUA status was only collected at a single time point
(n = 3), or AUA were only detected at the final study obser-
vation (n = 1).
AUA were detected in 6 of 75 observations (8.0%) at
week 16, in 7 of 64 observations (10.9%) at week 28, in 1 of
10 observations (10%) at week 40, in 4 of 42 observations
(9.5%) at week 52, and in 0 of 38 observations (0.0%) after
$64 weeks. The AUA titer in AUA-positive patients ranged
from 22 to 320 AU/mL. Median (range) serum trough con-
centrations were significantly lower in antibody-positive pa-
tients compared with antibody-negative patients; 0.02 mcg/
mL (,0.02–0.20) versus 0.30 mcg/mL (,0.02–3.80), respec-
tively, (P , 0.001). A good response was significantly more
frequently achieved in AUA-negative patients compared with
AUA-positive patients (44.1% versus 22.2%, P = 0.032),
Figure 2.
In patients on MTX comedication, 1 of 15 patients
(6.7%) developed AUA compared with 11 of 122 patients
(9.0%) on ustekinumab monotherapy, with no statistically
significant differences between groups (P = 0.77).
HLA-Cw6 Genotyping
HLA-Cw6 status was determined in 61 of 137 patients
(44.5% of study population). Prevalence of HLA-Cw6 posi-
tivity was 41%. Most of the demographic characteristics were
comparable between HLA-Cw6–positive and HLA-Cw6–
negative patients, except for age at onset of psoriasis and
prevalence of psoriatic arthritis. HLA-Cw6–positive patients
developed psoriasis at an earlier age (21.4 versus 31.6 years, P
= 0.012), and the prevalence of psoriatic arthritis was higher
(although not significant) in HLA-Cw6–negative patients (28.6
versus 8.3%, P = 0.098). No statistically significant differ-
ence in clinical response (assessed $16 weeks) between
TABLE 1. Patient Demographics
Age in yr, mean (SD) 50.0 (612.6)
Male sex, No (%) 96 (70.1)
BMI in kg/m2, mean (SD) 28.9 (66.1)
Psoriasis disease duration in yr, mean
(SD)
23.6 (612.8)
Diagnosis of PsA, No (%) 30 (21.9)
Concomitant methotrexate, No (%) 15 (10.9)
Previous biologic treatment, No (%) 105 (76.6)
PASI baseline, mean (SD) 14.1 (67.4)
BMI, body mass index; PsA, psoriasis arthritis.
De Keyser et al Ther Drug Monit  Volume 41, Number 5, October 2019
636 Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of
Therapeutic Drug Monitoring and Clinical Toxicology.
Cw6-positive and Cw6-negative patients could be demon-
strated (P = 0.164), although on average, slightly better
response rates in Cw6-positive patients were observed (Fig. 3).
DISCUSSION
The prevalence of AUA development was 8.7%, which
is comparable with the prevalence rates reported in the current
literature (1%–11%)9,18–20 but much lower than observed for
other biologics such as adalimumab and infliximab. AUA-
positivity significantly reduced serum trough concentrations
and impaired clinical response. These data are supported by
previously reported findings suggesting a trend toward
decreased treatment response with the formation of
AUA.18,21,22
In this cohort, AUA did develop during the first 52
weeks of ustekinumab treatment. However, the number of
observations obtained in the first year of ustekinumab
treatment (n = 191) was higher compared with the number
of observations obtained in patients .1 year on ustekinumab
FIGURE 1. Box-and-whisker plot showing usteki-
numab trough concentrations across response
groups. No statistically significant difference in
serum trough concentrations was found between
nonresponders, moderate responders, and good
responders (P = 0.948). The limits of the boxes
represent the interquartile (IQ) range. The line in
the boxes is the median. The whiskers extend
from the upper and lower edge of the box to the
highest and lowest values, which are no greater
than 1.5 times the IQ range. The circles and as-
terisks indicate outliers (values between 1.5 and 3
times the IQ range) and extreme outliers (values
more than 3 times the IQ range), respectively.
FIGURE 2. Clinical response according to AUA
status. A good response was significantly more
frequent achieved in AUA-negative patients com-
pared with AUA-positive patients (44.1% versus
22.2%, P = 0.032).
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treatment (n = 38), which might underestimate the prevalence
of AUA formation after long-term ustekinumab treatment.
We did not find a significant association between
ustekinumab serum trough concentrations and clinical response.
This observation is in line with the findings of Menting et al.19
An optimal ustekinumab threshold trough concentration as sug-
gested in other inflammatory diseases can therefore not yet be
recommended. In a cohort study by Toro-Montecinos et al,23
maintenance trough concentrations of ustekinumab in Crohn
disease above 4.5 mcg/mL at 26 weeks or later were identified
to correspond to an optimal clinical effect.
In a small number of patients (1.7%) in our cohort,
undetectable ustekinumab serum trough concentrations were
measured. This could be partly explained by the presence of
antidrug antibodies. Other factors that could have contributed
to this include patient’s nonadherence, total clearance of us-
tekinumab at the time of serum sample collection, or inade-
quate detection of serum trough concentrations in patients
with severe and active psoriasis in which all ustekinumab is
bound to IL-12 and IL-23.
For anti–tumor necrosis factor inhibitors, a significant
association between immunomodulatory comedication (eg,
MTX) and serum trough concentrations has been demonstrated
in several studies.24–26 In our study, MTX comedication did
not significantly impact ustekinumab serum concentrations,
which might be partly due to the low incidence of AUA.
However, results should be interpreted with caution due to the
small number of patients on MTX comedication. The thera-
peutic impact of MTX in patients on ustekinumab needs to be
confirmed by future studies with sufficient power.
In this cohort, we included patients treated with
ustekinumab for a minimum of 16 weeks. More and more
data arise showing that early pharmacokinetic drug measure-
ments, that is, during induction phase, might be predictive for
drug concentrations and clinical response on maintenance
treatment. Recently, Wilkinson et al27 reported on a large ada-
limumab cohort of 544 psoriasis patients and demonstrated that
early drug concentration measurements (obtained between 1
and 12 weeks) were predictive for clinical response at 6
months. Whether measurement of ustekinumab early in treat-
ment will help to make strategic treatment decisions is cur-
rently unknown and will be a valuable topic for future research.
With regard to pharmacogenetic markers, HLA-Cw6
has been suggested to potentially predict clinical response in
psoriasis patients on ustekinumab.28–31 We observed a slight
increase in response to ustekinumab in HLA-Cw6–positive
patients compared with HLA-Cw6–negative patients, but
the differences were small and not statistically significant.
Several studies have elaborated on single-nucleotide poly-
morphisms other than HLA-Cw6 and detected an association
between some of these polymorphisms and response to uste-
kinumab treatment.31–33 These results will have to be further
explored to assess whether pharmacogenetic markers can play
a role in the prediction of response to ustekinumab.
Our study has some limitations. First, it is still not an
extensive patient population, especially to draw conclusions
on whether HLA-Cw6 status can predict clinical response.
Second, not all possible factors that might influence treatment
response to ustekinumab (eg, topical therapy and adherence)
were considered. Third, the data were collected at different
time points, and serial measurements were collected only in
part of the patients (43.8%), which might impact the detection
of, for example, AUA formation.
CONCLUSIONS
Based on available evidence and our study results, we
conclude that there is currently overall insufficient evidence
FIGURE 3. Clinical response according to HLA-
Cw6 status. There was no statistically significant
difference in response between HLA-Cw6–positive
and HLA-Cw6–negative patients (P = 0.164).
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to support the use of serum trough concentrations or HLA-
Cw6 status to guide treatment decisions in ustekinumab
patients. Measurement of AUA in ustekinumab patients
should be considered if treatment response is unsatisfactory.
Future research is needed to gain a better understanding
on ustekinumab pharmacokinetics and pharmacodynamics
and to identify additional tools for therapeutic drug monitor-
ing in psoriasis patients on ustekinumab treatment.
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